The first batch of Lumito's reagent intended for end customer sales is now produced by Lumito's production partner, Uniogen Oy.
Lumito has collaborated with Uniogen Oy (formerly Kaivogen Oy) for over 15 months to prepare the production of the nanoparticle-based reagent kit belonging to the company's digital pathology solution.
– It feels great that a crucial ingredient in our solution now is produced so that we are completely ready when the next piece of the puzzle comes into place and then be able to launch SCIZYS, comments Mattias Lundin, Lumitos CEO.
SCIZYS Erbium Kit forms an essential part of the company's first product, which also consists of a digital scanner.
For further information, please contact:
Mattias Lundin, CEO Lumito
E-mail: ml@lumito.se
Ph: +46 76 868 45 09
Lumito
Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en
The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.
Image Attachments
SCIZYS Erbium Kit